Active, not recruitingNCT04475926
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
Studying Alpha-sarcoglycan-related limb-girdle muscular dystrophy R3
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarepta Therapeutics, Inc.
- Principal Investigator
- Medical DirectorSarepta Therapeutics, Inc.
- Enrollment
- 205 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2021 – 2030
Study locations (26)
- Barrow Neurological Institute, Phoenix, Arizona, United States
- Arkansas Children's, Little Rock, Arkansas, United States
- University of California San Diego, La Jolla, California, United States
- University of California, Davis Health Dept of PM&R, Sacramento, California, United States
- Anne & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- University of Utah Hospital, Salt Lake City, Utah, United States
- Children's Hospital of the King's Daughters, Norfolk, Virginia, United States
- University Hospital Gent, Ghent, Oost-Vlaanderen, Belgium
- UZ Leuven, Leuven, Vlaams Brabant, Belgium
- Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium
- Hospital de Clinicas de Porto Alegre (HCPA) - PPDS, Porto Alegre, Rio Grande do Sul, Brazil
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04475926 on ClinicalTrials.gov